Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Cisplatin for Recurrent Laryngeal Squamous Cell Carcinoma
NCT07392580Phase 2Recruiting
- Sponsor
- University of Miami
- Start
- Dec 2026
- Primary completion
- Sep 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin in laryngeal squamous cell carcinoma (LSCC), sponsored by University of Miami. Primary endpoint: Overall Pathologic Response Rate at 6 weeks. Planned start Dec 2026; status: recruiting.
02
Drugs
cisplatin
03
Conditions
laryngeal squamous cell carcinoma (LSCC)
Beyond the preview
Go deeper on NCT07392580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07392580.